Amyotrophic Lateral Sclerosis Treatment Market: Rising Demand and Emerging Opportunities

The global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 762.79 Million in 2024 and is expected to grow to USD 813.89 Million in 2025, reaching USD 1,367.36 Million by 2033 at a CAGR of 6.7%. Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a neurodegenerative disorder affecting nerve cells in the central nervous system, leading to progressive loss of voluntary muscle control. Patients often experience muscle twitching, stiffness, weakness, and may lose the ability to swallow, speak, walk, or use their hands. Nearly half of ALS patients succumb to respiratory failure within three to five years of diagnosis. Sporadic ALS is the most common type, accounting for 90–95% of U.S. cases, while familial ALS accounts for the remainder.

Download Sample

Market Growth Factors

The market growth is primarily driven by the rising prevalence of ALS. This fatal neuromuscular disease affects all races and ethnicities but is more common in white people, men, non-Hispanics, those in their 60s, and those with a family history. Increasing awareness and epidemiological studies indicate a growing global incidence.

Market Restraining Factors

High treatment costs remain a significant challenge. The mean annual cost of ALS per patient is estimated at EUR 78,256, with a lifetime cost reaching EUR 246,184, placing a substantial economic burden on patients and healthcare systems.

Market Opportunities

The growing geriatric population is creating opportunities for market expansion. By 2050, one in six people worldwide will be over 65, increasing the prevalence of age-related neurological disorders like ALS and driving demand for treatment solutions.

Regional Insights

North America dominates the market, with a CAGR of 6.55%. The U.S. is the largest contributor due to its aging population and increasing ALS cases. Asia-Pacific is projected to grow at a CAGR of 6.80%, with China leading the regional market due to rising ALS prevalence and a rapidly aging population. Germany, Brazil, and countries in the Middle East and Africa are also experiencing market growth due to similar demographic trends.

Treatment Insights

The market is divided into Medication and Others, with the medication segment contributing the most and growing at a CAGR of 6.45%. FDA-approved drugs include Rilutek (riluzole) and Radicava (edaravone), which help slow disease progression and prolong survival. Additional treatments include physical therapy, speech therapy, nutritional support, respiratory care, and emerging stem cell therapies such as NurOwn (MSC-NTF cells).

Distribution Channel Insights

Hospital pharmacies are the leading distribution channel, growing at a CAGR of 7.20%, due to structured pharmaceutical procurement and high patient inflow. Retail pharmacies and other channels, including online pharmacies, clinics, and ALS centers, are gaining popularity, providing convenient access to medications and therapies.

Key Players

  • Sun Pharmaceutical Industries Ltd

  • Corestem Inc.

  • BrainStorm Cell Limited

  • Amylyx Pharmaceuticals Inc.

  • AB Science

  • Ionis Pharmaceuticals

  • Biohaven Pharmaceutical

  • Biogen Inc.

  • Novartis AG

Recent Developments

  • June 2022ALBRIOZA (AMX0035) approved in Canada by Amylyx Pharmaceuticals Inc.

  • May 2022RADICAVA ORS approved by the U.S. FDA for ALS treatment by Mitsubishi Tanabe Pharma America

About Us:

Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.

Contact Us:

Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/

Leia Mais